Rejuvenation Biotechnology 2016 will be Held at the Buck Institute in California
Rejuvenation Biotechnology 2016 is the latest in a series of conferences hosted by the SENS Research Foundation, focused on bringing together industry and academia to pave the way for the advent of first generation rejuvenation therapies. The first of these therapies are already in clinical development, each narrowly focused on one cause of aging, such as senescent cell clearance at Oisin Biotechnologies and some of the SENS Research Foundation's own drug candidates for breaking down damaging metabolic waste at Human Rejuvenation Technologies. There are numerous other examples I could give, for either work based on the SENS vision of controlling aging through repair of cell and tissue damage, or other initiatives with less ambitious goals. If all goes well, they will be available in clinics outside the US within a few years, and have passed through the regulatory system inside the US at most a decade from now.
Building a whole new field of medicine and getting it into the clinic doesn't just magically occur, however. This is a big deal, and requires allies, advocacy, setting expectations, and either pulling in the heavyweight support of Big Pharma or creating an entirely new network of distribution and validation akin to the medical tourism industry for stem cell therapies. Laying these foundations for the work that lies ahead is one of the goals of the Rejuvenation Biotechnology conferences. You can look back in the Fight Aging! archives to read about the 2014 and 2015 conferences; well attended and well spoken of. You might take a look at this year's program for a sense of how the theme will follow on from prior years. Rejuvenation Biotechnology 2016 is being held at the Buck Institute for Research on Aging just North of the Bay Area, California. It is invitation only, I'm afraid - the wages of success and popularity - so if you feel the need to attend, you should contact the SENS Research Foundation folk and ask. The conference will be streamed live this year, however, so no-one need miss out.
Rejuvenation Biotechnology 2016, August 16-17
World populations are aging, and the social and economic burdens of age-related disease are rising steeply. For an increasing number of elderly individuals, healthcare is too often reduced to crisis management in the emergency room, painfully harsh treatments for diseases such as cancer, or best efforts at palliative care.
SENS Research Foundation exists to end aging. Since 2009 we have worked to make the concept of rejuvenation biotechnology - the repairing of the damage which occurs to our bodies as we age - into a reality. Our research, education and awareness programs have created the foundations of the Rejuvenation Biotechnology Industry, an industry that will be capable of targeting the diseases of aging with genuine, effective, affordable cures.
The 2016 Rejuvenation Biotechnology Conference is focused on taking the Rejuvenation Biotechnology Industry to the next level by addressing the question: what will it take to push emerging breakthroughs in regenerative medicine from proof-of-concept to implementation? This year's conference seeks to answer this critical inquiry by covering all the stages from securing funding, to production, to navigating regulation, to clinical evaluation and adoption of new treatments. Industry-leading experts will present real-life examples drawn from their own work followed by an open panel discussion and Q&A. As with our previous conferences, we provide ample time for networking with industry leaders, funders and researchers.
Due to our limited space the 2016 Rejuvenation Biotechnology Conference is an invitation-only event. In order for our entire community to be able to participate we will be live streaming the conference and everyone is invited to join us via the live stream. To stay in the loop for our live streaming, please register today.
"If all goes well, they will be available in clinics outside the US within a few years, and have passed through the regulatory system inside the US at most a decade from now."
Reason, I know you did the disclaimer, "If all goes well", but wow, if there is starting to be treatment within a few years (in <5 years would be great) available, that would be incredible. First, just having something very shortly specifically for aging would be awesome. But, even more so, to build from the first treatments and improve upon that to eventually attain LEV.
IMO, getting to the first treatments for aging is the most difficult. But, once there, it is just adding more (effective) treatment for LEV.
And, hugely, when the (first available treatments) is in the marketplace, controlling aging should become more mainstream for the public and we would then seen more VC's (I.E. funding) getting into the field.
Myself, I would wait 5 years after first availability to avoid any unforeseen side effects.
@Robert Church: I'd actually say that getting the first treatments out there is difficult in a different way from expanding and improving to the point of reaching LEV. The latter requires a hundred or a thousand times the work to reach the goal. The former is more of a bootstrapping and advocacy situation, changing the minds of the world. In the 2030s advancing the treatment of aging to be better and more comprehensive will look like cancer research does today from the perspective of how people see it, and the type of institutions that grow around it.
@Reason, My thought/view is that once treatments become available and even if they don't allow one to reach LEV (yet), I would think (ok, hope), that it would increase many peoples lives to reach LEV. I.E., one reaches the age of 70 in 2025 and there are say 3 or 4 different treatments at that point to help avoid getting cancer and other diseases for, say, another 10 years, then said person could make it for another 5-10 years of living, beyond the average age of someone getting cancer.
Probable this is the same as what Ray K. states, that we may be adding more years (to our lives) very soon, maybe beginning in 5-10 years out. It seems reasonable (w/o sounding too biased) given continued advancement in medical knowledge and tech.